New Delhi: The interval between two dosages of the Covishield Covid-19 vaccine was extended based on scientific evidence and the decision was taken in a transparent manner, said NK Arora, the chairman of NTAGI.
There was no dissenting voice among the members of the National Technical Advisory Group on Immunization (NTAGI ), he said, according to a tweet by the Union Health Ministry.
“We have a very open, transparent system where decisions are taken on a scientific basis. The Covid Working Group took that decision, with no dissenting voice. The issue was then discussed threadbare at the NTAGI meeting, with no dissenting notes,” said Arora.
The government had on 13 May said it has accepted the Covid-19 Working Group’s recommendation and extended the gap between the two doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks.
“Based on the available real-life evidence, particularly from the UK, the Covid-19 Working Group agreed for increasing the dosing interval to 12-16 weeks between two doses of Covishield vaccine. No change in the interval of Covaxin vaccine doses was recommended,” the Ministry had said in a statement.